|
1
|
Vetter MH and Hays JL: Use of targeted
therapeutics in epithelial ovarian cancer: A review of current
literature and future directions. Clin Ther. 40:361–371. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morris CR, Sands MT and Smith LH: Ovarian
cancer: Predictors of early-stage diagnosis. Cancer Causes Control.
21:1203–1211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mallory AC and Bouché N: MicroRNA-directed
regulation: To cleave or not to cleave. Trends Plant Sci.
13:359–367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen K and Rajewsky N: The evolution of
gene regulation by transcription factors and microRNAs. Nat Rev
Genet. 8:93–103. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bell E and Taylor MA: Functional roles for
exosomal microRNAs in the tumour microenvironment. Comput Struct
Biotechnol J. 15:8–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mahdian-Shakib A, Dorostkar R, Tat M,
Hashemzadeh MS and Saidi N: Differential role of microRNAs in
prognosis, diagnosis, and therapy of ovarian cancer. Biomed
Pharmacother. 84:592–600. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Erdmann K, Kaulke K, Rieger C, Salomo K,
Wirth MP and Fuessel S: miR-26a and miR-138 block the G1/S
transition by targeting the cell cycle regulating network in
prostate cancer cells. J Cancer Res Clin Oncol. 142:2249–2261.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rizzo M, Berti G, Russo F, Fazio S,
Evangelista M, D'Aurizio R, Pellegrini M and Rainaldi G:
Discovering the miR-26a-5p targetome in prostate cancer cells. J
Cancer. 8:2729–2739. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding K, Wu Z, Wang N, Wang X, Wang Y, Qian
P, Meng G and Tan S: miR-26a performs converse roles in
proliferation and metastasis of different gastric cancer cells via
regulating of PTEN expression. Pathol Res Pract. 213:467–475. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pastuszak-Lewandoska D, Kordiak J,
Czarnecka KH, Migdalska-Sęk M, Nawrot E, Domańska-Senderowska D,
Kiszałkiewicz JM, Antczak A, Górski P and Brzeziańska-Lasota E:
Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d,
in relation to MMP-2 expression level in non-small cell lung cancer
patients: A pilot study. Med Oncol. 33:962016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin G, Liu B, Meng Z, Liu Y, Li X, Wu X,
Zhou Q and Xu K: miR-26a enhances invasive capacity by suppressing
GSK3β in human lung cancer cells. Exp Cell Res. 352:364–374. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song Q, Liu B, Li X, Zhang Q, Cao L, Xu M,
Meng Z, Wu X and Xu K: miR-26a-5p potentiates metastasis of human
lung cancer cells by regulating ITGβ8- JAK2/STAT3 axis. Biochem
Biophys Res Commun. 501:494–500. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong Y, Wu W, Zou X, Liu F, Wei T and Zhu
J: miR-26a inhibits thyroid cancer cell proliferation by targeting
ARPP19. Am J Cancer Res. 8:1030–1039. 2018.PubMed/NCBI
|
|
15
|
Liu P, Tang H, Chen B, He Z, Deng M, Wu M,
Liu X, Yang L, Ye F and Xie X: miR-26a suppresses tumour
proliferation and metastasis by targeting metadherin in triple
negative breast cancer. Cancer Lett. 357:384–392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cabello P, Pineda B, Tormo E, Lluch A and
Eroles P: The antitumor effect of metformin is mediated by miR-26a
in breast cancer. Int J Mol Sci. 17:12982016. View Article : Google Scholar :
|
|
17
|
Zhao XX, Yuan QZ, Mu DP, Sun DW, Bo QA,
Pan GZ, Li GQ, Cui T, Ding PP, You FP, et al: MicroRNA-26a inhibits
proliferation by targeting high mobility group AT-hook 1 in breast
cancer. Int J Clin Exp Pathol. 8:368–373. 2015.PubMed/NCBI
|
|
18
|
Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y,
Xu X, Wu J, Li S, Mao Q, et al: miR-26a inhibits proliferation and
motility in bladder cancer by targeting HMGA1. FEBS Lett.
587:2467–2473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun M, Zhao X, Liang L, Pan X, Lv H and
Zhao Y: Sialyltransferase ST3GAL6 mediates the effect of
microRNA-26a on cell growth, migration, and invasion in
hepatocellular carcinoma through the protein kinase B/mammalian
target of rapamycin pathway. Cancer Sci. 108:267–276. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma Y, Deng F, Li P, Chen G, Tao Y and Wang
H: The tumor suppressive miR-26a regulation of FBXO11 inhibits
proliferation, migration and invasion of hepatocellular carcinoma
cells. Biomed Pharmacother. 101:648–655. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao XM, Zhu Y, Li JH, Wang XY, Zhang XF,
Yi CH and Yang X: MicroRNA-26a induces a mitochondrial apoptosis
mediated by p53 through targeting to inhibit Mcl1 in human
hepatocellular carcinoma. Onco Targets Ther. 11:2227–2239. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jinushi T, Shibayama Y, Kinoshita I,
Oizumi S, Jinushi M, Aota T, Takahashi T, Horita S, Dosaka-Akita H
and Iseki K: Low expression levels of microRNA-124-5p correlated
with poor prognosis in colorectal cancer via targeting of SMC4.
Cancer Med. 3:1544–1552. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu B, Pan S, Xiao Y, Liu Q, Xu J and Jia
L: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer
progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway.
J Exp Clin Cancer Res. 37:3162018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
ParvizHamidi M, Haddad G, Ostadrahimi S,
Ostadrahimi N, Sadeghi S, Fayaz S and Fard-Esfahani P: Circulating
miR-26a and miR-21 as biomarkers for glioblastoma multiform.
Biotechnol Appl Biochem. 66:261–265. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao J, Zeng K, Liu Y, Gao L and Liu L:
LncRNA SNHG5 promotes growth and invasion in melanoma by regulating
the miR-26a-5p/TRPC3 pathway. Onco Targets Ther. 12:169–179. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Z, Zhao L, Zhao F, Yang G and Wang J:
MicroRNA-26b regulates cancer proliferation migration and cell
cycle transition by suppressing TRAF5 in esophageal squamous cell
carcinoma. Am J Transl Res. 8:1957–1970. 2016.PubMed/NCBI
|
|
27
|
Thorsen K, Schepeler T, Øster B, Rasmussen
MH, Vang S, Wang K, Hansen KQ, Lamy P, Pedersen JS, Eller A, et al:
Tumor-specific usage of alternative transcription start sites in
colorectal cancer identified by genome-wide exon array analysis.
BMC Genomics. 12:5052011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
L'Abbate A, Tolomeo D, De Astis F, Lonoce
A, Lo Cunsolo C, Mühlematter D, Schoumans J, Vandenberghe P, Van
Hoof A, Palumbo O, et al: T(15;21) translocations leading to the
concurrent downregulation of RUNX1 and its transcription factor
partner genes SIN3A and TCF12 in myeloid disorders. Mol Cancer.
14:2112015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Labreche K, Simeonova I, Kamoun A, Gleize
V, Chubb D, Letouzé E, Riazalhosseini Y, Dobbins SE, Elarouci N,
Ducray F, et al: TCF12 is mutated in anaplastic oligodendroglioma.
Nat Commun. 6:72072015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang X, Hou Y, Yang G, Wang X, Tang S, Du
YE, Yang L, Yu T, Zhang H, Zhou M, et al: Stromal miR-200s
contribute to breast cancer cell invasion through CAF activation
and ECM remodeling. Cell Death Differ. 23:132–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen YF, Yang CC, Kao SY, Liu CJ, Lin SC
and Chang KW: MicroRNA-211 enhances the oncogenicity of
carcinogen-induced oral carcinoma by repressing TCF12 and
increasing antioxidant activity. Cancer Res. 76:4872–4886. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hertz DL and McLeod HL: Integrated patient
and tumor genetic testing for individualized cancer therapy. Clin
Pharmacol Ther. 99:143–146. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ichimura A, Ruike Y, Terasawa K and
Tsujimoto G: miRNAs and regulation of cell signaling. FEBS J.
278:1610–1618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Svoronos AA, Engelman DM and Slack FJ:
OncomiR or tumor suppressor? The duplicity of microRNAs in cancer.
Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Moles R: MicroRNAs-based therapy: A novel
and promising strategy for cancer treatment. Microrna. 6:102–109.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Deb B, Uddin A and Chakraborty S: miRNAs
and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lu YY, Lin Y, Ding DX, Su S, Chi QQ, Zhang
YC, Sun J, Zhang X, Zhu HM, Huang QS, et al: miR-26a functions as a
tumor suppressor in ambient particulate matter-bound
metal-triggered lung cancer cell metastasis by targeting
LIN28B-IL6-STAT3 axis. Arch Toxicol. 92:1023–1035. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang L, Li K and Guo T: miR-26a-5p
suppresses tumor metastasis by regulating EMT and is associated
with prognosis in HCC. Clin Transl Oncol. 19:695–703. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun TY, Xie HJ, He H, Li Z and Kong LF:
miR-26a inhibits the proliferation of ovarian cancer cells via
regulating CDC6 expression. Am J Transl Res. 8:1037–1046.
2016.PubMed/NCBI
|
|
42
|
De Lima AB, Silva LM, Gonçales NG,
Carvalho MRS, da Silva Filho AL and da Conceição Braga L:
Three-dimensional cellular arrangement in epithelial ovarian cancer
cell lines TOV-21G and SKOV-3 is associated with apoptosis-related
miRNA expression modulation. Cancer Microenviron. 11:85–92. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gao S, Bian T, Zhang Y, Su M and Liu Y:
TCF12 overexpression as a poor prognostic factor in ovarian cancer.
Pathol Res Pract. 215:1525272019. View Article : Google Scholar : PubMed/NCBI
|
